Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Korea.
Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.
Korean J Radiol. 2018 Sep-Oct;19(5):819-831. doi: 10.3348/kjr.2018.19.5.819. Epub 2018 Aug 6.
The aim of this systematic review was to describe the characteristics of prostate-specific membrane antigen (PSMA)-targeting PET and their clinical applications in prostate cancer patients. There have been major strides in the design, synthesis of PSMA-targeting PET tracers over the past several years. PSMA-targeting PET tracers can be categorized, according to positron emitters and targeting strategies for the PSMA. The majority of PSMA PET studies has been focused on patients with biochemical recurrence, but additional values of PSMA PET have also been investigated for use in primary staging, treatment planning, response evaluation, and PSMA radioligand therapy. PSMA PET is expected to bring improvements in the management of patients, but the impact of improved diagnosis by PSMA on overall survival remains unanswered. Many challenges still await PSMA PET to expedite the use in the clinical practice. At this early stage, prospective multicenter trials are needed to validate the effectiveness and usefulness of PSMA PET.
本系统评价的目的是描述前列腺特异性膜抗原（PSMA）靶向 PET 的特征及其在前列腺癌患者中的临床应用。在过去的几年中，PSMA 靶向 PET 示踪剂的设计和合成取得了重大进展。根据 PSMA 的正电子发射体和靶向策略，PSMA 靶向 PET 示踪剂可以进行分类。大多数 PSMA PET 研究集中在生化复发患者，但也研究了 PSMA PET 的其他价值，用于原发分期、治疗计划、反应评估和 PSMA 放射性配体治疗。PSMA PET 有望改善患者的管理，但 PSMA 改善诊断对总生存的影响仍未得到解答。PSMA PET 仍面临许多挑战，需要加快在临床实践中的应用。在现阶段，需要前瞻性多中心试验来验证 PSMA PET 的有效性和实用性。
